We are live on ! Find out more
JB

Julian Baker Baker Bros. Advisors

AUM $20B
1-Year Est. Return 154.41%
 

Julian Baker is co-managing member of Baker Bros. Advisors, a firm renowned for deep specialization in biotechnology and life sciences. The firm is known for concentrated positions, long holding periods, and scientific diligence that goes well beyond typical generalist research. Baker Bros. filings are closely watched by healthcare investors for signals in clinical-stage and commercial biotech.

This Fund
S&P 500
This Quarter Est. Return
-9.76%
1 Year Est. Return
+154.41%
3 Year Est. Return
+448.58%
5 Year Est. Return
+670.61%
10 Year Est. Return
+4,743.65%
AUM
$16.2B
AUM Growth
-$2.57B
Cap. Flow
+$150M
Cap. Flow %
0.93%
Top 10 Hldgs %
86.32%
Holding
116
New
17
Increased
25
Reduced
19
Closed
6

Top Buys

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$49.3M
2
ACAD icon
Acadia Pharmaceuticals
ACAD
+$43.3M
3
KOD icon
Kodiak Sciences
KOD
+$31.6M
4
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$27.5M
5
ALLK
Allakos
ALLK
+$27.1M

Top Sells

Rank Stock Value
1
EXAS
Exact Sciences
EXAS
+$60M
2
BOLD
Audentes Therapeutics, Inc
BOLD
+$48.2M
3
ADPT icon
Adaptive Biotechnologies
ADPT
+$10.4M
4
QURE icon
uniQure
QURE
+$9.23M
5
NXTC icon
NextCure
NXTC
+$8.45M

Sector Composition

Rank Sector Weight
1 Healthcare 99.65%
2 Financials 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IDYA icon
101
IDEAYA Biosciences
IDYA
$3.83B
$522K ﹤0.01%
126,611
-73,389
-37% -$520K
ADMS
102
DELISTED
Adamas Pharmaceuticals
ADMS
$499K ﹤0.01%
172,630
– –
INFI
103
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$486K ﹤0.01%
580,400
– –
GNFT
104
DELISTED
Genfit
GNFT
$395K ﹤0.01%
+26,696
New +$454K
AFMD
105
DELISTED
Affimed
AFMD
$316K ﹤0.01%
20,000
– –
VIRX
106
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$231K ﹤0.01%
15,905
– –
OVID icon
107
Ovid Therapeutics
OVID
$547M
$207K ﹤0.01%
+69,471
New +$234K
CTMX icon
108
CytomX Therapeutics
CTMX
$715M
$153K ﹤0.01%
20,000
-174,377
-90% -$1.22M
DVAX
109
DELISTED
Dynavax Technologies
DVAX
– –
-75,000
Closed -$429K
NXTC icon
110
NextCure
NXTC
$28.8M
– –
-12,500
Closed -$8.45M
YMAB
111
DELISTED
Y-mAbs Therapeutics
YMAB
– –
-138,514
Closed -$4.33M
FSTX
112
DELISTED
F-star Therapeutics, Inc. Common Stock
FSTX
– –
-153,286
Closed -$969K
TRIL
113
DELISTED
Trillium Therapeutics Inc.
TRIL
– –
-1,100,000
Closed -$1.13M
BOLD
114
DELISTED
Audentes Therapeutics, Inc
BOLD
– –
-804,720
Closed -$48.2M
1 2 3 4
5

Similar funds

ASRS
Arizona State Retirement System Phoenix, Arizona $19.9B AUM 44.71% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
CWP
Capital Wealth Planning Naples, Florida $20B AUM 25.34% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

Julian Baker's Q1 2020 Portfolio in Review

As of Q1 2020, Julian Baker held 116 positions worth $16.2B, down 14% from $18.8B the previous quarter. Its ten largest holdings account for 86% of the portfolio.

Julian Baker's Q1 2020 filing shows 17 new, 25 increased, 19 reduced and 6 closed positions. Its largest new stake was Adaptimmune Therapeutics: 3,690,307 shares worth $10M. The largest sale was Exact Sciences, an estimated $60M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Financials.

  • Julian Baker's largest Q1 2020 buy was Adaptimmune Therapeutics: 3,690,307 shares worth $10M.
  • Julian Baker added most to Alexion Pharmaceuticals in Q1 2020, an estimated $49.3M increase.
  • Julian Baker's biggest Q1 2020 reduction was Exact Sciences, cutting an estimated $60M.
  • Julian Baker fully exited Audentes Therapeutics, Inc in Q1 2020, selling an estimated $48.2M.
  • Julian Baker's ten largest holdings make up 86% of its $16.2B portfolio in Q1 2020.
  • Julian Baker opened 17 new positions and closed 6 in Q1 2020.
  • Julian Baker's portfolio value fell 14% quarter-over-quarter to $16.2B.

Based on Baker Bros. Advisors's 13F filing for Q1 2020, filed 15 May 2020.